

appeared asymptomatic⁴⁵. Another serological study detected SARS-CoV-2 neutralizing antibodies in cat serum samples collected in Wuhan after the COVID-19 outbreak, providing evidence for SARS-CoV-2 infection in cat populations in Wuhan, although the potential of SARS-CoV-2 transmission from cats to humans is currently uncertain⁴⁶.

Receptor use and pathogenesis

SARS-CoV-2 uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2)^{11,47}. Besides human ACE2 (hACE2), SARS-CoV-2 also recognizes ACE2 from pig, ferret, rhesus monkey, civet, cat, pan-golin, rabbit and dog^{11,43,48,49}. The broad receptor usage of SARS-CoV-2 implies that it may have a wide host range, and the varied efficiency of ACE2 usage in different animals may indicate their different susceptibilities to SARS-CoV-2 infection. The S1 subunit of a coronavirus is further divided into two functional domains, an N-terminal domain and a C-terminal domain.

Structural and biochemical analyses identified a 211 amino acid region (amino acids 319–529) at the S1C-terminal domain of SARS-CoV-2 as the RBD, which has a key role in virus entry and is the target of neutralizing antibodies^{50,51} (FIG. 3a). The RBD mediates contact with the ACE2 receptor (amino acids 437–507 of SARS-CoV-2 S protein), and this region in SARS-CoV-2 differs from that in SARS-CoV in the five residues crit-